Executive summary
US 8,586,045 is a method-of-treatment patent that claims use of a specific human or humanized anti-CGRP antagonist monoclonal antibody (including defined CDRs, epitope targeting to CGRP C-terminal residues 25-37, binding affinity threshold, and particular VH/VL and ATCC cell line vectors) for reducing vasomotor symptoms and for treating headache subtypes, including migraine. The estate’s practical enforceability in the US depends on whether an accused product is (1) an anti-CGRP antagonist antibody with the claimed sequence/epitope constraints, and (2) administered in claimed dosing and administration formats. Entry risk for competitors is therefore concentrated around “literal identity” to the claimed antibody (CDRs/VH-VL/ATCC vectors) or around prosecution-history-supported equivalents to those sequence and epitope limitations, plus whether the product targets CGRP (vs CGRP receptor) and whether it binds the CGRP C-terminal 25-37 region.
US 8,586,045 claims overview: what exactly is protected?
Core claim structure
The independent claims (1 and 17 in your excerpt) recite:
- A method for reducing incidence of or treating:
- vasomotor symptoms (claim 1), and
- headache in a human (claim 17).
- An “anti-CGRP antagonist antibody” that is:
- human monoclonal or humanized monoclonal.
Key dependent-claim constraints that narrow scope
The dependent claims add multiple technical gates that materially narrow the antibody identity and performance:
-
Specific CDRs (sequence-defined antibody)
- Claim 2: CDR H1 (SEQ ID NO:3), H2 (SEQ ID NO:4), H3 (SEQ ID NO:5), L1 (SEQ ID NO:6), L2 (SEQ ID NO:7), L3 (SEQ ID NO:8) or variants shown in Table 6.
-
Binding affinity threshold
- Claim 4 / 20: Kd ≤ 50 nM to human α-CGRP at 37°C by surface plasmon resonance.
-
Defined VH/VL sequence (numbered sequences)
- Claim 5 / 21: VH comprises SEQ ID NO:1 and VL comprises SEQ ID NO:2.
-
Defined production system identity (ATCC vectors/cell lines)
- Claim 6 / 22: light chain produced by an expression vector with ATCC Accession No. PTA-6866.
- Claim 7 / 23: heavy chain produced by an expression vector with ATCC Accession No. PTA-6867.
-
Epitope limitation
- Claim 10 / 25: antibody binds the CGRP C-terminal fragment (amino acids 25–37) or an epitope within amino acids 25–37.
-
Effector function impairment
- Claim 11 / 26: Fc region with impaired effector function.
-
Administration routes
- Claim 12 / 27: systemic including IV, SC, IM, transdermal.
-
IgG2 constant region
- Claim 13 / 28: heavy chain constant region derived from human IgG2.
-
Formulation
- Claim 14 / 29: pharmaceutically acceptable carrier/excipient/stabilizer.
-
Humanized
- Claim 15 / 30: “humanized monoclonal antibody” (separate from claim 1’s “human or humanized” base).
-
Dose floor
- Claim 16 / 31: dose at least about 3 μg/kg.
What the claims do NOT appear to cover (based on your excerpt)
- No explicit CGRP receptor antagonist language (it is CGRP-directed as “anti-CGRP antagonist antibody”).
- No explicit receptor-binding versus ligand-binding mode beyond epitope and CGRP binding Kd.
- No device-based, combination therapy, or specific infusion regime beyond dose floor and route.
H3. Functional implication: the patent is an antibody-identity + use claim
Even though the independent claims read broadly as “method … administering an anti-CGRP antagonist antibody,” the dependent claims hardwire sequence-defined and epitope-defined antibody characteristics. That increases validity stability relative to pure functional “antibody that blocks CGRP,” but it increases infringement difficulty for products that are CGRP antibodies yet use distinct CDRs, sequences, epitope regions, Fc, IgG class, or production vectors.
What patents protect CGRP antibody treatment for migraine and vasomotor symptoms beyond US 8,586,045?
US 8,586,045 sits in the broader CGRP biologics landscape where multiple patent families typically exist around:
- antibody sequences (CDRs, framework, VH/VL),
- epitope mapping,
- humanization methods,
- Fc engineering (impaired effector function),
- formulation and delivery,
- dosing regimens and patient subsets,
- and regulatory use claims (migraine, cluster, vasomotor symptoms/menopausal hot flushes).
Competitive context
In the US, the most litigated and commercially significant CGRP antibody programs include (non-exhaustive) antibodies marketed for migraine prophylaxis/acute treatment. For competitors and litigators, the key is that many CGRP antibodies are ligand-neutralizing antibodies (vs receptor antagonists), and many have Fc modifications that reduce effector function. The differentiator for US 8,586,045 is whether an accused antibody matches its sequence and epitope requirements (especially the C-terminal 25–37 region) and whether infringement theories can avoid those limitations.
H3. Family overlap risk: antibody sequence claims often dominate
When a biologic product is covered by separate sequence claims, method claims like US 8,586,045 often serve as an additional hook for enforcement (including “use” enforcement against clinicians/hospitals/dispensers). But sequence-defined dependent claims mean enforcement often collapses to whether the product antibody is within the defined CDR/variant space.
How strong is the patent estate for US 8,586,045 based on claim narrowing features?
1) Strengthors
- Multiple, orthogonal narrowing parameters (CDR sequences + VH/VL sequences + epitope + Kd + IgG2 Fc impairment + ATCC vector IDs + dose floor). This can make the claims less susceptible to prior-art invalidity if those characteristics were not disclosed together.
- Epitope constraint to residues 25–37 provides a technical handle beyond generic “binds CGRP.”
2) Vulnerabilities
- Literal infringement fragility: many next-gen CGRP antibodies differ in CDRs, epitope regions (some bind CGRP core vs tail), Fc class, or production constructs. Even small sequence differences can avoid the CDR-defined limitations.
- Variant claim scope depends on Table 6: claim 2 and claim 18 cover “variants … as shown in Table 6.” If Table 6’s variant definitions are narrow (commonly they are), a competitor can design around. If Table 6 is broad, the risk increases.
- ATCC vector accession numbers are a hard identity marker: claiming light/heavy chain produced by specific ATCC expression vectors can limit infringement to products that use those exact constructs or their direct equivalents.
H3. Infringement theory realism
For a defendant, the main defense line is: the accused antibody does not match the defined CDRs/VH/VL and/or does not bind the CGP R C-terminal 25–37 region; it also may not meet Kd ≤ 50 nM or the IgG2 constant region and Fc impairment limitation. For a plaintiff, enforcement is strongest when the accused antibody is the same or a very close variant of the sequence-identified antibody.
When does US 8,586,045 lose exclusivity in the US?
No answerable timeline from the provided input
You have provided claims text but not the patent’s filing date, priority date, issue date confirmation, or any PTA/adjustment/terminal disclaimer information. Without those, an accurate US exclusivity/expiration date cannot be produced.
What generic entry risks exist for anti-CGRP antibodies with method-of-use claims like US 8,586,045?
General reality for CGRP antibodies
- These products are biologics; generic entry is typically biosimilar entry, not “small-molecule generic.”
- Method claims can be asserted against prescribing and administration, but biosimilar “labeling” and “use” alignment matter.
Specific risk drivers for US 8,586,045
- Biosimilar similarity must extend to the antibody epitope and sequence-defined regions to trigger literal infringement of the dependent claims (CDR/VH/VL constraints and Table 6 variants).
- Label wording: if a biosimilar’s approved indications include the claimed vasomotor symptoms and/or migraine subtypes, and its route and dosing align, a method-of-use infringement theory becomes more plausible.
- Device of design-around: competitors can select anti-CGRP antibodies that still bind CGRP but differ in the CGRP tail epitope (25–37) and CDR architecture to avoid these specific claim elements.
How do US 8,586,045’s vasomotor symptom claims compare with migraine-only CGRP antibody claims?
US 8,586,045 intentionally spans two clinical areas:
- Vasomotor symptoms (claim 3 list includes hot flush and several headache disorders).
- Headache (claim 17 list includes migraine with/without aura, hemiplegic migraine, cluster headache, migrainous neuralgia, chronic headache, tension headache).
Strategic effect
- Broad indication coverage can expand the number of potential infringing administrations.
- But the antibody constraints remain the gating factor.
H3. Potential label and enforcement leverage
For enforcement, the most leverage typically occurs where a product’s label directly uses the claimed condition language (“migraine,” “hot flushes”) and includes a dose range above the dose floor (≥ 3 μg/kg) for at least one administration route recited.
What does “anti-CGRP antagonist antibody” mean for infringement: ligand binding versus receptor binding?
The claims emphasize:
- Binding to human α-CGRP with Kd ≤ 50 nM (SPR at 37°C).
- Binding the CGRP C-terminal fragment amino acids 25–37.
That frames the antibody as a CGRP-binding antagonist (blocking ligand activity). Infringement focus therefore centers on whether the antibody binds CGRP in the claimed region and with the claimed binding affinity threshold, not merely whether it produces an anti-migraine clinical effect.
What is the Orange Book status of US 8,586,045 and how does it matter?
Not determinable from the provided input
US 8,586,045 is a patent; Orange Book listings require drug product identifiers and the Orange Book database record. No such mapping was provided.
What patent litigation affects US 8,586,045 and its enforceability?
Not determinable from the provided input
No litigation docket numbers, parties, filings, or court venues were provided, and none can be generated reliably from the claim text alone.
Key claim-by-claim critical analysis: likely strongest and weakest elements
Claim 1 (vasomotor + anti-CGRP human/humanized antibody)
- Strongest if the product’s antibody is within the claimed antibody identity (sequence and epitope).
- Otherwise weak as a standalone because “anti-CGRP antagonist antibody” without sequence constraints can be too generic, but your dependent claims provide the actual narrowing.
Claim 2 (CDRs and variants in Table 6)
- Usually the strongest single element for infringement and validity, if Table 6 variant definitions are tight.
Claim 4 / 20 (Kd ≤ 50 nM)
- Strong for technical differentiation; requires measured data comparability.
- Weak if assay/conditions differ or if defense challenges measurement method.
Claims 5/6/7 (SEQ ID VH/VL + ATCC vectors)
- Powerful as identity markers but also creates design-around freedom (different vectors/constructs, different expression design).
Claim 10 / 25 (C-terminal 25–37 epitope)
- High discrimination if competing antibodies bind different epitope regions.
- In practice, epitope mapping can be disputed.
Claims 11/13 (Fc impaired effector function + IgG2 constant region)
- These features differentiate against antibodies with different Fc classes or effector-function profiles.
Claims 12/27 (routes)
- If a product is IV/SC/IM, it likely falls inside. If it is nasal or oral delivery, it may fall outside.
Claims 14/29 (formulation)
- Often less critical for infringement unless accused products use a specific carrier/stabilizer claim that is disclosed and tied to the patent.
Claims 15/30 (humanized)
- Helps if an accused antibody is not humanized (pure human antibodies would still be “human,” but some claims are phrased “humanized monoclonal”; depending on dependent claim interpretation, human-only products may not fall under that dependent limitation).
Claims 16/31 (dose ≥ 3 μg/kg)
- Provides a quantitative infringement boundary. If product labels prescribe lower dose levels, a route-and-dose carve-out can emerge.
Claims 17-31 (headache methods)
- Mirror the vasomotor portion with indication-specific symptom lists; enforcement depends on label indication and dosing.
Key Takeaways
- US 8,586,045 protects method-of-use of a specific anti-CGRP antagonist monoclonal antibody for vasomotor symptoms and headache (including migraine subtypes).
- The claim set is narrowed by sequence-defined CDRs/VH/VL, variant-defined scope (Table 6), epitope binding to CGRP residues 25–37, binding affinity Kd ≤ 50 nM, IgG2 Fc impairment, and ATCC vector accession IDs, plus a dose floor (≥ 3 μg/kg).
- Enforceability against a commercial CGRP antibody product is therefore most likely when the accused antibody is close in sequence and epitope, and when the product’s approved indication, administration route, and dosing align with the claimed method.
FAQs
- How does the CGRP C-terminal 25–37 epitope limitation affect infringement for alternative anti-CGRP antibodies?
- If a biosimilar has similar clinical efficacy for migraine, what claim elements in US 8,586,045 still need to match for method-of-use infringement?
- Does an “anti-CGRP antagonist antibody” product that targets the CGRP receptor instead of ligand binding fall outside US 8,586,045?
- How do the ATCC PTA-6866 and PTA-6867 identifiers constrain infringement theories in practice?
- What matters more for method-of-use risk: label wording for migraine/vasomotor symptoms or the antibody’s binding affinity and epitope mapping?
References
- US Patent 8,586,045 (claims excerpt provided by user).
